Evidence map›Paper›PMID 28737661›Full record

ArticleTransplantation2017

Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops.

Allison Tong, John Gill, Klemens Budde, Lorna Marson, Peter P Reese, David Rosenbloom, Lionel Rostaing, Germaine Wong, Michelle A Josephson, Timothy L Pruett and 23 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyConsensus Statement
In one paragraph

Article in Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06474273 (A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant Recipients), which is not on this map. Cited by 60 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 5 pooled it
48.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06474273 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant Recipients

TypeinterventionalSponsorUniversity of SydneyRan2026 to 2030Enrolled540ConditionsRejection, Transplant, Kidney, Rejection, Transplant, PancreasArmsMethylprednisolone, Prednisone
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Antihypertensive treatment for kidney transplant recipients.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Guideline
  3. Pooled it
  4. Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Pooled it
  5. Patient-reported outcome measures for life participation in peritoneal dialysis: a systematic review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Pooled it
  6. Occupational Priorities of People on Hemodialysis Who Participated in Energy Management Education.Canadian journal of occupational therapy. Revue canadienne d'ergotherapie · 2025
    Trial
  7. Using a measurement type-independent metric to compare patterns of determinants between patient-reported versus performance-based physical function in hemodialysis patients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 8 countries.

Allison Tong1 Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. 2 Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. 3 Division of Nephrology, University of British Columbia, Vancouver, BC, Canada. 4 Department of Nephrology, Charité-Universitätsmedizin Berlin, Germany. 5 Transplant Unit, University of Edinburgh, Edinburgh, United Kingdom. 6 Renal Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States. 7 ESRD Network 18, Los Angeles, CA. 8 Clinique Universitaire de Nephrologie, CHU Michallon, Grenoble, France. 9 Centre for Transplant and Renal Research, Westmead Hospital, NSW, Westmead, Australia. 10 Department of Medicine, The University of Chicago, Chicago, IL. 11 Department of Surgery, University of Minnesota, Minneapolis, MN. 12 School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. 13 Department of Nephrology and Clinical Immunology, University Francois Rabelais, Tours Hospital, Tours, France. 14 INSERM, U1246, Tours, Franc Tours, France. 15 Department of Nephrology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA. 16 William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, MA. 17 Jockey Club Nephrology & Urology Centre, Princess Margaret Hospital, Hong Kong. 18 The University of Hong Kong, Queen Mary Hospital, Hong Kong. 19 Department of Nephrology, Monash Medical Centre, Melbourne, Australia. 20 Depatment of Renal Medicine, Singapore General Hospital, Singapore.
John Gill
Klemens Budde
Lorna Marson
Peter P Reese
David Rosenbloom
Lionel Rostaing
Germaine Wong
Michelle A Josephson
Timothy L Pruett
Anthony N Warrens
Jonathan C Craig
Benedicte Sautenet
Nicole Evangelidis
Angelique F Ralph
Camilla S Hanson
Jenny I Shen
Kirsten Howard
Klemens Meyer
Ronald D Perrone
Daniel E Weiner
Samuel Fung
Maggie K M Ma
Caren Rose
Jessica Ryan
Ling-Xin Chen
Martin Howell
Nicholas Larkins
Siah Kim
Sobhana Thangaraju
Angela Ju
Jeremy R Chapman
SONG-Tx Investigators
Children's Hospital at Westmead · AUThe University of Sydney · AUUniversity of British Columbia · CAUniversity of Edinburgh · GBCentre Hospitalier Universitaire de Grenoble · FRMonash Medical Centre · AUTufts Medical Center · USUniversity of Hong Kong · HKUniversity of Minnesota · USWestmead Hospital · AU

Funding

TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007357 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 1986 to 2022
$4.8M
Trajectories of Adherence to Cardiovascular Medications in Patients on DialysisK23DK103972 · NIDDK · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SHEN, JENNY I · 2015 to 2019
$934k
NIDDK NIH HHS K23 DK103972NIDDK NIH HHS T32 DK007357
6 · The paper itself

Abstract

backgroundTreatment decisions in kidney transplantation requires patients and clinicians to weigh the benefits and harms of a broad range of medical and surgical interventions, but the heterogeneity and lack of patient-relevant outcomes across trials in transplantation makes these trade-offs uncertain, thus, the need for a core outcome set that reflects stakeholder priorities.

methodsWe convened 2 international Standardized Outcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops in Boston (17 patients/caregivers; 52 health professionals) and Hong Kong (10 patients/caregivers; 45 health professionals). In facilitated breakout groups, participants discussed the development and implementation of core outcome domains for trials in kidney transplantation.

resultsSeven themes were identified. Reinforcing the paramount importance of graft outcomes encompassed the prevailing dread of dialysis, distilling the meaning of graft function, and acknowledging the terrifying and ambiguous terminology of rejection. Reflecting critical trade-offs between graft health and medical comorbidities was fundamental. Contextualizing mortality explained discrepancies in the prioritization of death among stakeholders-inevitability of death (patients), preventing premature death (clinicians), and ensuring safety (regulators). Imperative to capture patient-reported outcomes was driven by making explicit patient priorities, fulfilling regulatory requirements, and addressing life participation. Specificity to transplant; feasibility and pragmatism (long-term impacts and responsiveness to interventions); and recognizing gradients of severity within outcome domains were raised as considerations.

conclusionsStakeholders support the inclusion of graft health, mortality, cardiovascular disease, infection, cancer, and patient-reported outcomes (ie, life participation) in a core outcomes set. Addressing ambiguous terminology and feasibility is needed in establishing these core outcome domains for trials in kidney transplantation.

Indexed as

Delphi TechniqueClinical Trials as TopicHumansKidney TransplantationNephrologyTreatment Outcome

Identifiers

PMID28737661
PMCPMC5604246
OpenAlexW2605408553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.